Trias Joaquim 4
4 · Anthera Pharmaceuticals Inc · Filed Mar 5, 2010
Insider Transaction Report
Form 4
Trias Joaquim
SR VP, Preclinical Development
Transactions
- Conversion
Common Stock
2010-03-04+17,523→ 174,166 total - Conversion
Series A-1 Convertible Preferred Stock
2010-03-04−17,523→ 0 total→ Common Stock (17,523 underlying)
Footnotes (2)
- [F1]Each share of Series A-1 Convertible Preferred Stock was automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]The Series A-1 Convertible Preferred Stock has no expiration date.